Rats produce high rates of ultrasonic vocalizations (USVs) in social situations; these vocalizations are influenced by multiple neurotransmitter systems. Norepinephrine (NE) plays a significant role in vocalization biology; however, the contribution of NE to normal, prosocial vocal control has not been well established in the rat. To address this, we used NE adrenoceptor agonists (Cirazoline, Clonidine) and antagonists (Prozasin, Atipamezole, Propranolol) to quantify the contribution of specific alpha-1, alpha-2, and beta NE receptors to USV parameters in male Long Evans rats during seminaturalistic calling. We found that multiple USV acoustic variables (intensity, bandwidth, duration, peak frequency, and call profile) are modified by alterations in NE signaling. Very generally, agents that increased NE neurotransmission (Atipamezole) or activated alpha-1 receptors (Cirazoline), led to an increase in intensity and duration, respectively. Agents that decreased NE neurotransmission (Clonidine) or blocked alpha-1 receptors (Prazosin) reduced call rate, intensity, and bandwidth. However, the beta-receptor antagonist, Propranolol, was associated with increased call rate, duration, and intensity. Limb motor behaviors were largely unaffected by any drug, with the exception of Clonidine. Higher doses of Clonidine significantly reduced gross motor, grooming, and feeding behavior. These results confirm the involvement of NE transmission in vocal control in the rat, and suggest that this USV model is useful for studying the neuropharmacology of behavioral measures that may have implications for disease states, such as Parkinson's disease.
throughout the central and peripheral nervous system, however the ␣ 2 -AR is primarily located presynaptically and functions as an autoreceptor that, when stimulated, reduces NE release (Fornai, Alessandrì, Fascetti, Vaglini, & Corsini, 1995; Rommelfanger & Weinshenker, 2007) , although these categorizations are not absolute and more complex roles for ␣2 receptors have been found. This system is conserved across vertebrates (Smeets & González, 2000) , acts to coordinate and activate multiple brain activities ( Aston-Jones & Cohen, 2005; Berridge & Waterhouse, 2003; Chamberlain & Robbins, 2013; Marien, Colpaert, & Rosenquist, 2004) , and is well positioned to influence vocalizations.
Male adult rats emit 50-kHz frequency-modulated ultrasonic vocalizations in a variety of social situations, including in response to female conspecifics. Rats produce several types of USVs that can be classified by complexity and frequency characteristics of the waveform (Ciucci et al., 2007; Ciucci & Connor, 2009; Knutson, Burgdorf, & Panksepp, 2002; Portfors, 2007; Wöhr, Houx, Schwarting, & Spruijt, 2008) . USV produced in a sociosexual paradigm are composed of short, constant frequency calls (simple calls) as well as complex frequency modulated subtypes (Brudzynski, 2005; Burgdorf, Wood, Kroes, Moskal, & Panksepp, 2007; Ciucci et al., 2007 McGinnis & Vakulenko, 2003; Wöhr et al., 2008) . There is pharmacological evidence that suggests noradrenergic involvement in vocal behavior (Heimovics, Cornil, Ellis, Ball, & Riters, 2011; Riters & Pawlisch, 2007; Wright, Dobosiewicz, & Clarke, 2012; Wright et al., 2013) . For example, administration of the ␣2 NE receptor agonist Clonidine increases calling in rat pups (Kehoe & Harris, 1989) . Additionally, differential stimulation of alpha and beta adrenergic receptors elicits 50-kHz vocalizations in amphetamine-induced calling in rats (Wright et al., 2012) . While these previous finding suggests a potential role for NE receptor modulation of rodent vocalizations, how NE regulates specific acoustic components of this behavior remains unclear. Moreover, the relative contributions of the three major NE receptor subtypes (␣1, ␣2, ␤) to acoustic properties of calls have not been determined in a prosocial (induction of conspecific behavioral responses including approach) communication model. Given the potential clinical relevance of vocalization behaviors, particularly in disorders such as Parkinson's disease where there is presumed NE system dysfunction (Barclay et al., 1996; Chamberlain & Robbins, 2013; Grant et al., 2014 , it is useful to understand the precise function of NE receptors in promoting and/or reducing different forms of vocalization.
The purpose of this study was to determine how NE ARs modulate specific acoustic parameters in the rat. Specifically, we hypothesized that selectively targeting NE receptors would result in the differential modulation of pertinent acoustic properties of USV including intensity, bandwidth, peak frequency, and duration, in addition to general parameters such as call profile and call rate. We also hypothesized that locomotor and limb behavior would be influenced in a dose-dependent manner. Due to the paucity of information in the literature about NE regulation of vocal behavior, we optimized our paradigm to detect either increases or decreases in the various parameters under study. Thus, we could determine whether NE AR activity was necessary and/or sufficient for each of these measures.
Method Animals, Habituation, and Experimental Overview
Fifty male Long-Evans (Charles River) rats, aged 4 -5 months, were used in this study. Rats were randomized into one of five groups (n ϭ 10 per group) that received three doses of a specific NE receptor drug and vehicle, described below. An additional 8 females, aged 2-12 months were used to elicit USV, and not included in analyses. Prior to all testing, male rats were handled and acclimated to experimental procedures 5 days a week for a total of 2 weeks. Rats were pair-housed in standard polycarbonate cages (17 cm ϫ 28 cm ϫ 12 cm) on a reverse 12:12 hr light cycle. All testing occurred under partial red-light illumination during the dark cycle, as rats are nocturnal. Food and water were available ad libidum. All procedures were approved by the University of Wisconsin-Madison School of Medicine and Public Health Animal Care and Use Committee, and are consistent with the NIH guidelines on the Care and Use of Laboratory Animals.
Separate groups of rats were used to test each drug (n ϭ 10/drug for a total of n ϭ 50). Each of the five drugs (agonists or antagonists for ␣1, ␣2, or ␤ NE receptors) was administered (intraperitoneal [i.p.]) in a within-subjects design. Thus, each rat received a total of four injections (three doses plus vehicle) in a counterbalanced (Latin square) order. Injections were separated by three days for wash-out (see Table 1 ). For each injection, rats were placed individually in the test cage (homecage with bedding) for 30 min (min) to acclimate to the testing room. Following this period of acclimation, each rat received an injection and was placed back in the home cage alone for 20 -30 min (see Table 1 ), depending on the pharmacokinetic properties of each drug. Drug doses and pharmacological windows were based on published work (Bialer et al., 2004; Conway & Jarrott, 1980; Elghozi, Bianchetti, Morselli, & Meyer, 1979; Jaillon, 1980; Jaiswal & Mallick, 2009; Wright et al., 2012) . Then, locomotor activity was Note. AR ϭ adrenoceptor; ip ϭ intraperitoneal; min ϭ minutes; mg/kg ϭ milligrams/kilogram. This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. measured, followed immediately by USV testing (also described below). Rats remained isolated from their cage-mates for the duration of injection and testing periods only and remained dually housed for the nontesting portions of the study.
Drug Treatments
Doses, receptor targets, and timings for drug administration are shown in Table 1 and Figure 1 . Each of the following drugs was dissolved in 0.9% sterile isotonic saline and injected at a dose of 1 mg/kg: Cirazoline HCL (PubChem CID: 11957512; Sigma Aldrich); Prazosin HCL (PubChem CID: 68,546; MP Biomedicals, LLC); Clonidine HCL (PubChem CID: 20,179; Sigma Aldrich); Atipamezole (PubChem CID: 71,310; Sigma Aldrich); Propranolol hydrochloric acid (HCL; PubChem CID: 62,882; Sigma Aldrich) was prepared in distilled water with 5% DMSO (Sigma Aldrich), and sonicated until dissolved. Drug doses and time course windows were based on published work (Bialer et al., 2004; Conway & Jarrott, 1980; Elghozi et al., 1979; Jaillon, 1980; Jaiswal & Mallick, 2009; Wright et al., 2012) .
Ultrasonic Vocalization Recording and Analysis
USV were recorded with an ultrasonic microphone with a flat frequency response up to 150 kHz, a working frequency-response range of 10 -180 kHz (CM16, Avisoft, Germany), 16-bit resolution and sampled at 250 kHz. The microphone was mounted 15 cm above a standard polycarbonate rat cage. Each male rat was paired with a sexually receptive (estrus) female in the homecage (cage mate temporarily rehoused). After the male demonstrated interest in the female (sniffing, mounting, chasing), the female was removed and male-only vocalizations were recorded for 90 seconds (sec).
Offline acoustic analysis was completed by two raters masked to experimental condition with a customized automated program using SASLab Pro (Avisoft, Germany). Spectrograms were built from each waveform with the frequency resolution set to an FFT of 512 points, a frame size of 100% and flat top window, and the temporal resolution set to display 75% overlap. Extraneous low frequency noise was removed from the spectrogram using a highpass filter set to exclude noise below 25 kHz (Johnson et al., 2011) . Variables measured included: latency to the first call (sec), call rate (number of calls/sec; calculated as the total number of calls for the first 60 seconds after calling commenced, divided by 60), overall call profile (% of individual call type; Table 2 ), and standard deviation of intensity (described below).
To determine call profile, individual calls were classified using a modified version of the 'call profile classification scheme' developed and used previously (Wright, Gourdon, & Clarke, 2010; Wright et al., 2012) : flat, step, short, ramp, trill, harmonic, frequency modulated (FM), and compound (see Figure 2) . For analyses of all other acoustic variables, calls were grouped to the broad categories of simple, complex, and compound (Ciucci et al., 2007 Ringel, Basken, Grant, & Ciucci, 2013;  see Figure 2 ). For this study, the following variables were obtained for each rat within the broad category: bandwidth (Hz), peak frequency (kHz), duration (sec), and intensity or "loudness" (decibels [dB]) Johnson, et al., 2011; Riede, 2013 Riede, , 2014 and are reported as mean and standard error of the mean (SEM).
During recording, rats moved freely around the cage, resulting in variable mouth-to-mic distance that may affect intensity measures. In our experience, the impact of this movement and inherent variability in mouth-to-mic distance is negligible as all rats are tested in the exact same manner and produce calls in all parts of the cage, resulting in an equally heterogeneous sample of call intensity across animals. However, to account for this quantitatively, we calculated the standard deviation of intensity (dB) during each recording session as a gross indication of the range of intensities produced by each rat under each drug condition.
Locomotor Activity and Latency to Mount
To measure alterations in gross motor function resulting from a drug, locomotor activity was assayed. After drug administration was allowed to reach peak effect (20 -30 min), each rat was Drug, target, effect Latency to Call Figure 1 . Modulation of noradrenergic receptors directly influences rat ultrasonic vocalizations. Alterations following the administration of each drug as compared to saline. Smallest cells within each column designate low (L), medium (M), and high (H) dose for each respective drug. Solid black indicates a decrease at a particular dose, diagonal lines indicate an increase, and blank (white) indicates no change. AR ϭ adrenoreceptor; V ϭ "Decreases" norepinephrine transmission; ⌳ ϭ "Increases" norepinephrine transmission. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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recorded in their home-cage using a digital camera (Sony HDR-CX210, New York, NY) for 20 min. Videos were analyzed offline by three experienced raters masked to condition for the following variables: total number of cage crossings, total number of rears, time spent grooming (sec), and time spent eating (sec). Latency to first mount (sec) the female was measured during USV testing to quantify the males' interest in the female. Typically, well-acclimated rats will demonstrate interest and attempt to mount within 1-2 min of exposure to a female. However, occasionally, a rat did not mount within 5 min. This did not happen often, and as all male rats were sexually experienced as part of the study acclimation procedures, had mounted on previous occasions, and showed other signs of interest (chasing, sniffing) the female was removed and vocalizations were recorded.
Statistical Analysis
Separate single-factor (drug dose) repeated measures analyses of variance (ANOVAs) were carried out on each variable for each drug. All data were tested for normality (Shapiro-Wilk test) and equal variances; if the data failed to meet the assumptions for ANOVA, rank or log transformations were used. When significant main effects were seen, post hoc comparisons were made using Fisher's LSD. The critical level of significance was determined a priori at p Ͻ .05. Differences in degrees of freedom reflect cases where the animal did not have the data point.
To determine the degree to which USV and locomotor data were reliably analyzed, an Intraclass Correlation Coefficient (ICC) was calculated on 5% of all the behavioral files analyzed to determine the inter-and intrarater reliability. A two-way ANOVA was run on each data set to determine mean squares and degrees of freedom, from which the ICC was computed.
Results
Each drug is described separately, ANOVA results for all USV and locomotor variables are detailed below, and means and standard error of the mean (SEM) are reported in the supplemental data (Supplemental Tables 1-5 ). All significant data are presented in Figures 3-8. The intra-and interrater reliability ICC index was above 0.90 for behavioral variables.
Cirazoline
Locomotor and latency to mount. There was a main effect of Cirazoline on the number of rears (F [3, 27] ϭ 4.29, p ϭ .013).
The total number of rears was significantly decreased following 0.125 mg/kg (p ϭ .019), 0.25 mg/kg (p ϭ .02), and 0.50 mg/kg (p ϭ .002) compared to vehicle. There were no effects on number of cage crossings, time spent eating, or time spent grooming (p Ͼ .05). There was not a main effect of Cirazoline on latency to mount (p Ͼ .05). See Supplemental Table 1 .
General vocalization properties. There was no effect of Cirazoline on call rate, latency to call, or standard deviation of intensity (p Ͼ .05; Supplemental Table 2 ). There was a main effect of drug treatment on the percent of flat calls (F [3, 27] ϭ 5.78, p ϭ .003). Specifically, compared to vehicle, the percent of flat calls was significantly reduced with 0.125 mg/kg (p ϭ .014), 0.25 mg/kg (p Ͻ .001), and 0.50 mg/kg (p ϭ Ͻ0.024) of Cirazoline (data not shown). There were no other significant effects of Cirazoline on call profile (p Ͼ .05; data not shown).
Duration. There was a main effect of drug treatment on duration of compound calls (F [3, 27] ϭ 4.24, p ϭ .014). Duration of compound calls was increased with the 0.50 mg/kg dose of Cirazoline compared to vehicle (p ϭ .011) and 0.125 mg/kg (p ϭ .003) ( Figure 4B ). There were no main effects of Cirazoline on duration of simple or complex calls (p Ͼ .05; Supplemental Table  3, 4) .
Bandwidth. There were no main effects of Cirazoline on bandwidth of simple, complex, or compound calls (p Ͼ .05; Supplemental Tables 3-5) .
Intensity. There were no main effects of Cirazoline on intensity for simple, complex, or compound calls (p Ͼ .05; Supplemental Tables 3-5) .
Peak frequency. There were no main effects of drug treatment on peak frequency of simple, complex or compound calls (p Ͻ .05; Supplemental Tables 3-5).
Prazosin
Locomotor and latency to mount. There was not a main effect of Prazosin on latency to mount (p Ͼ .05). There were also no main effects of drug treatment on the number of cage crossings, number of rears, time spent eating, time spent grooming or any of the locomotor variables (p Ͼ .05) (See Supplemental Table 1) .
General vocalization properties. There was a main effect of drug treatment on call rate (F [3, 27] ϭ 15.26, p Ͻ .001). Call rate was significantly decreased with 0.1 mg/kg (p ϭ .048), 0.3 mg/kg (p Ͻ .001), and 1.0 mg/kg (p Ͻ .001) of Prazosin compared to vehicle. Additionally, 0.3 mg/kg and 1.0 mg/kg Table 2 ). There was a main effect of drug treatment on the percent of compound (F [3, 27] This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
(p ϭ .005) and 1.0 mg/kg (p ϭ .022) doses compared to vehicle treatment (data not shown). The percent of frequency modulated calls was significantly reduced with the 0.1 mg/kg (p ϭ .013), 0.3 mg/kg (p Ͻ .001), and 1.0 mg/kg (p ϭ .049) doses compared to vehicle treatment. There was not a main effect of drug treatment on latency to call or any other call types (p Ͼ .05).
Duration. There were no main effects of drug treatment on duration for simple, complex, or compound calls (p Ͼ .05; Supplemental Tables 3-5) .
Bandwidth. There was a main effect of drug treatment on bandwidth of simple calls (F [3, 26] ϭ 3.76, p ϭ .023). Bandwidth of simple calls was reduced with 1.0 mg/kg of Prazosin compared to vehicle (p ϭ .003) ( Figure 5A ). There was no effect of Prazosin on bandwidth of complex or compound calls (p Ͼ .05; Supplemental Table 4 , 5).
Intensity. There was a main effect of drug treatment on intensity of simple calls (F [3, 26] ϭ 6.37, p ϭ .002). Intensity of simple calls was reduced with the 0.1 mg/kg (p ϭ .027), 0.3 mg/kg (p ϭ .005), and 1.0 mg/kg (p Ͻ .001) doses of Prazosin compared to vehicle ( Figure 7A ).
There was also a main effect of drug treatment on intensity of complex calls (F [3, 27] ϭ 12.14, p Ͻ 0.001). Intensity of complex calls was reduced with the 0.1 mg/kg (p ϭ .004), 0.3 mg/kg (p ϭ .005), and 1.0 mg/kg (p Ͻ .001) doses of Prazosin compared to vehicle and the 1.0 mg/kg dose was significantly reduced compared to the 0.1 mg/kg (p ϭ .007) and 0.03 mg/kg (p ϭ .006) doses ( Figure 7B ).
There was not an effect of Prazosin on intensity of compound calls (p Ͼ .05; Supplemental Table 5 ).
Peak frequency. There was no effect of Prazosin on peak frequency of simple, complex, or compound calls (p Ͼ .05; Supplemental Tables 3Ϫ5).
Clonidine
Locomotor and latency to mount. There was no effect of Clonidine on latency to mount (p Ͼ .05). There was a main effect of Clonidine on the total number of cage crossings (F [3, 26] Table 1 .
General vocalization properties. There was a main effect of drug treatment on latency to call (F [3, 26 ϭ 5.02, p ϭ .007). Rats commenced calling significantly later following the 0.1 mg/kg (p Ͻ .001) and 0.02 mg/kg (p ϭ .023) doses of Clonidine compared to vehicle. Latency to call was also significantly increased with the 0.1 mg/kg dose compared to the 0.01 mg/kg dose (p ϭ .035). There was a main effect of drug treatment on call rate (F [3, 25] ϭ 48.221, p Ͻ .001). Clonidine dose-dependently decreased call rate (p Ͻ .001 for all comparisons except 0.01 mg/kg compared to 0.02 mg/kg was p ϭ .004: Figure 3 ). See Supplemental This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
There was a main effect of drug treatment on the percent of frequency modulated (F [3, 25] ϭ 9.572, p Ͻ .001) and ramp calls (F [3, 25] ϭ 5.97, p ϭ .003). Rats produced fewer frequency modulated and ramp calls at the highest dose (0.1 mg/kg) compared to vehicle (p Ͻ .001; p ϭ .002, respectively), 0.01 mg/kg (p ϭ .001; p ϭ .023, respectively), and 0.02 mg/kg (p ϭ .002; p Ͻ .001, respectively). In addition, there was main effect of drug treatment on the percent of harmonic (F [3, 25] ϭ 4.0, p ϭ .019) and short calls (F (3, 25] ϭ 3.07, p ϭ .046). Harmonic and short calls were abolished at the highest dose. This was significantly different from vehicle (p ϭ .008) and 0.01 mg/kg (p ϭ .011) for harmonic calls and significantly different from vehicle (p ϭ .011) and 0.02 mg/kg (p ϭ .022) for short calls. There were no other main effects of drug treatment on call type (p Ͼ .05).
Duration. There was a main effect of drug treatment on duration of compound calls (F [3, 19] ϭ 3.18, p ϭ .048). Duration was increased with the highest dose of Clonidine (0.1 mg/kg) compared to vehicle (p ϭ .01), 0.01 mg/kg (p ϭ .011), and 0.02 mg/kg (p ϭ .033) ( Figure 4B ). There were no main effects of drug treatment on duration of simple or complex calls (p Ͼ .05; Supplemental Table 3 , 4). This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Bandwidth. There was a main effect of drug treatment on bandwidth of complex calls (F [3, 21] ϭ 12.13, p Ͻ .001). Bandwidth of complex calls was reduced in the 0.02 mg/kg and 0.1 mg/kg doses of Clonidine compared to vehicle (p ϭ .001 and p Ͻ .001, respectively) and 0.01 mg/kg (p Ͻ .001 and p ϭ .003, respectively; Figure 5B ).
There was a main effect of drug treatment on bandwidth of compound calls (F [3, 19] ϭ 7.37, p ϭ .002). Bandwidth of compound calls was reduced in the 0.01 mg/kg (p ϭ .018), 0.02 mg/kg (p ϭ .001), and 0.1 mg/kg (p Ͻ .001) doses of Clonidine compared to vehicle ( Figure 5C ). There was no effect of Clonidine on bandwidth of simple calls (p Ͼ .05; Supplemental Table 3 ).
Intensity. There was a main effect of drug treatment on intensity of simple calls (F [3, 23] ϭ 12.19, p Ͻ .001). Intensity of simple calls was significantly reduced (quieter) with the 0.1 mg/kg dose compared to vehicle (p Ͻ .001) and 0.01 mg/kg (p Ͻ .001) but increased (louder) compared to the 0.02 mg/kg (p ϭ .014). The 0.02 mg/kg dose was significantly reduced (quieter) compared to vehicle (p ϭ .004) and the 0.01 mg/kg dose (p ϭ .046) ( Figure  7A ).
There was a main effect of drug treatment on intensity of complex calls (F [3, 21] ϭ 4.34, p ϭ 0.016). Intensity of complex calls was significantly reduced with the 0.02 mg/kg dose compared to vehicle (p ϭ .002) and 0.01 mg/kg (p ϭ .029) ( Figure 7B ).
There was no effect of Clonidine on intensity of compound Calls (p Ͼ .05; Supplemental Table 4) .
Peak frequency. There was a main effect of drug treatment on peak frequency of simple calls (F [3, 23] ϭ 4.6, p ϭ .012) Peak frequency of simple calls was significantly reduced with the 0.1 mg/kg dose compared to vehicle (p ϭ .002), 0.01 mg/kg (p ϭ 0.006), and 0.02 mg/kg (p ϭ .021) ( Figure 6A ).
There was a main effect of drug treatment on peak frequency of complex calls (F [3, 21] ϭ 4.68, p ϭ .012). Peak frequency of complex calls was significantly reduced with the 0.1 mg/kg dose compared to vehicle (p ϭ .003), 0.01 mg/kg (p ϭ 0.008), and 0.02 mg/kg (p ϭ .003) ( Figure 6B ).
There was a main effect of drug treatment on peak frequency of compound calls (F [3, 19] ϭ 4.08, p ϭ .021). Peak frequency of compound calls was significantly reduced with the 0.1 mg/kg dose compared to vehicle (p Ͻ .001), 0.01 mg/kg (p ϭ 0.004), and 0.02 mg/kg (p Ͻ .001) ( Figure 6C ).
Atipamezole
Locomotor and latency to mount. There were no main effects of drug treatment on the number of cage crossings, number of rears, time spent eating, or time spent grooming (p Ͼ .05 for all). There was not an effect of Atipamezole on latency to mount (p Ͼ .05). See Supplemental Table 1 .
General vocalization properties. There was a main effect of drug treatment on the percent of step calls (F [3, 26] ϭ 4.18, p ϭ .015). Rats produced significantly more step calls with 0.3 mg/kg (p ϭ .028) and 1.0 mg/kg (p ϭ .003) of Atipamezole compared to vehicle and significantly more with 1.0 mg/kg compared to 0.1 mg/kg (p ϭ .035). Atipamezole did not have any other significant effects on call profile (p Ͼ .05). There were no main effects of Atipamezole on latency to call, call rate, or standard deviation of intensity (p Ͼ .05). This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Duration. There were no main effects of drug treatment on duration of simple, complex, or compound calls (p Ͼ .05; Supplemental Tables 3-5) .
Bandwidth. There were no effects of drug treatment on bandwidth of simple, complex, or compound calls (p Ͼ .05; Supplemental Tables 3-5) .
Intensity. There was a main effect of drug treatment on intensity of simple calls (F [3, 26] ϭ 3.7, p ϭ .024). Intensity was increased with the highest dose of Atipamezole, 1.0 mg/kg (p ϭ .008), and middle dose, 0.3 mg/kg (p ϭ .006), compared to the lowest dose, 0.1 mg/kg ( Figure 7A ). There was no effect of Atipamezole on the intensity of complex or compound calls (p Ͼ .05; Supplemental Table 4, 5).
Peak frequency. There were no main effects of drug treatment on peak frequency of simple, complex or compound calls (p Ͼ .05 for all; Supplemental Tables 3-5). This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Propranolol
Locomotor and latency to mount. There was no effect of Propranolol on latency to mount (p Ͼ .05) or the number of cage crossings, number of rears, time spent eating, or time spent grooming (p Ͼ .05). See Supplemental Table 1 .
General vocalization properties. There was a main effect of drug treatment on the call rate (F [3, 27] ϭ 3.00, p ϭ .048). Call rate was significantly increased with all the doses compared to vehicle (p ϭ .024, p ϭ .035, and p ϭ .013 for 0.3, 1.0, and 3.0 mg/kg, respectively). There was no effect of Propranolol on latency to call or standard deviation of intensity (p Ͼ .05). See Supplemental Table 2 .
Duration. There was a main effect of drug treatment on the duration of simple calls (F [3, 27] ϭ 3.52, p ϭ .028). Duration was increased with the highest dose, 3.0 mg/kg Propranolol compared to vehicle ( Figure 4A ). There were no main effects of drug treatment on duration of complex or compound calls (p Ͼ .05; Supplemental Table 4 , 5).
Bandwidth. There were no main effects of drug treatment on bandwidth of simple, complex or compound calls (p Ͼ 0.05; Supplemental Tables 3-5) .
Intensity. There was a main effect of Propranolol on the intensity of complex calls (F [3, 27] ϭ 3.540, p ϭ .028). Intensity of complex calls was significantly increased with the 1.0 mg/kg Figure 8 . Clonidine significantly reduces motor, grooming, and feeding activity. Bar graphs showing locomotor activity Ϯ standard error of the mean (SEM) for vehicle and three doses of Clonidine (low dose (light gray bar), medium dose (dark gray bar), and high dose (black bar)). (A) Total number of cage crossings was significantly reduced at all dose levels compared to vehicle. (B) Total number of rears was significantly reduced at all dose levels. (C) Total time (seconds (sec)) spent grooming was significantly reduced at all dose levels compared to vehicle. (D) Total time (sec) spent eating was significantly decreased at the highest dose. Bars and asterisks indicate significant differences resulting from planned post hoc analyses (
). This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. and 3.0 mg/kg doses of Propranolol (p ϭ .035 and p ϭ .004, respectively) compared to vehicle ( Figure 7B ). While there was no main effects of drug treatment on intensity of simple or compound calls (p Ͼ 0.05), there was a general trend toward increasing intensity with increasing dose. Peak frequency. There was a main effect of drug treatment on the peak frequency of simple (F [3, 27] ϭ 3.67, p ϭ .025) and complex (F [3, 27] ϭ 3.66, p ϭ .025) calls. There was a significant decrease in peak frequency of simple calls at 1.0 mg/kg (p ϭ .036) and 3.0 mg/kg (p ϭ .003) ( Figure 6A ) compared to vehicle. Similarly, there was a significant decrease in peak frequency of complex calls at 1.0 mg/kg (p ϭ .007) and 3.0 mg/kg (p ϭ .012) ( Figure 6B ).
Discussion
We hypothesized that pharmacological manipulation of the noradrenergic system would have a direct effect on rat vocalizations and the results of the present study indicate that specific acoustic properties of USV can be modulated by noradrenergic mechanisms. Specifically, this study found that an ␣2 receptor agonist (Clonidine) or ␣1 receptor antagonist (Prazosin) decreased call rate, and a ␤ receptor antagonist (Propranolol) increased call profile, while an ␣1 receptor agonist or an ␣2 receptor antagonist (Cirazoline and Atipamezole, respectively) had no effect on call rate. This work establishes that modulation of NE-ARs results in changes in general USV features such as call rate and profile as previously observed (Wright et al., 2012) , and NE receptor subtypes contribute differentially to pertinent aspects of USV such as intensity (loudness), bandwidth, duration, and peak frequency.
Adrenoceptors Differentially Modulated Ultrasonic Calls
Modulation of specific noradrenergic receptor subtypes (␣ 1 -, ␣ 2 -and ␤-AR) with agonists and antagonists results in differential effects on call rate as well as the types of calls produced (call profile). We found that Cirazoline resulted in a dose-dependent decrease in the number of flat calls without affecting call rate. In addition, we observed dose-dependent effects of Cirazoline on the average duration of compound calls (increased). Prazosin, on the other hand, dose-dependently decreased call rate, significantly reduced the percent of compound and frequency modulated calls, and decreased bandwidth of compound calls. Intensity was also reduced for simple and complex calls. These findings indicate that the ␣ 1 -AR is important for mediating not only the number of calls produced (Wright et al., 2012) , but may also contribute to the control of bandwidth, duration, and intensity.
We found that Atipamezole resulted in dose dependent increases in the number of step calls and average intensity of simple calls. In contrast, Clonidine, resulted in increased latency to call, dose dependent decreases in call rate, the percent of frequency modulated, ramp, harmonic, and short calls. Duration of compound calls was increased, while bandwidth was dose-dependently reduced for compound and complex calls. Intensity was reduced for simple and complex calls, and peak frequency was reduced for all calls. Given that Clonidine has been shown to have sedative effects (Drew, Gower, & Marriott, 1979) , it is possible that the broad locomotor (see below) and USV effects observed here are related to level of arousal. Propranolol was the only drug that dose-dependently increased call rate and intensity of complex calls. We also saw decreases in peak frequency of simple and complex calls, and increased duration of simple calls with Propanolol. Again, these findings suggest that NE-ARs, specifically the ␤-AR and ␣ 2 -AR, may be important for mediating intensity, or loudness, of USV. In general, these findings indicate that specific noradrenergic mechanisms contribute to vocal control, but the relationship is not linear.
In the current study, we found that drugs that antagonize ␣ 1 -AR (Prazosin) or reduced NE release (by agonizing presumptive ␣2 autoreceptors (Clonidine)) resulted in significant reductions in multiple USV parameters. Clonidine resulted in decreased complexity of call profile (frequency modulated, harmonic, ramp, and short calls were all reduced and most calls were flat), dosedependently reduced call rate, and reduced intensity, bandwidth, and peak frequency. Similarly, Prazosin altered call profile (reduced compound and frequency-modulated calls) and reduced call rate, bandwidth, and intensity. This trend was not universal; however, as the ␤ receptor antagonist Propranolol resulted in increased call rate and intensity. Despite this exception, the results of this study indicate that decreasing NE transmission at the ␣ 1 -AR (Prazosin) and ␣ 2 -AR (Clonidine) results in quantitatively negative effects on call rate, intensity, peak frequency, and bandwidth. Although increasing NE transmission or stimulating ␣1 NE receptors directly had relatively few effects, these effects were uniform in nature. Atipamezole resulted in increased intensity (loudness) at the two highest doses, as well as more step-calls. Similarly, at the highest dose, Cirazoline resulted in increased duration at and an increase in the number of flat calls. No decreases in any acoustic parameters were observed following Atipamezole or Cirazoline.
Locomotor Activity
In addition to vocalizations, we also evaluated locomotor activity as a measure of gross sensorimotor function. We found that Prazosin, Atipamezole, and Propranolol did not have any effect on the number of cage crossings, number of rears, times spent eating, or time spent grooming, yet these compounds did change USV. The number of rears was dose-dependently decreased following Cirazoline, but the only effect on USV was on duration of compound calls. Clonidine dose-dependently decreased all aspects of locomotor activity and significantly affected USV. Additionally, latency to call was only increased with Clonidine. Given that rats vocalize when moving around, we cannot rule out the possibility that the effects of Clonidine on latency to call and USV parameters were due to general sedation effects (Drew et al., 1979) . However, locomotion alone does not, in and of itself result in vocalizations (Knutson et al., 2002) . In the present study, we found compounds that affected USV without altering locomotion. Therefore, altered locomotion in neither necessary nor sufficient to affect USV.
Current Findings in Relation to Previous Studies
The results of this study generally support previous work with amphetamine-induced rat USV and add to what is known about the contribution of noradrenergic mechanisms to vocal control. We found reductions in call rate with Clonidine and Prazosin and no changes in call rate with Atipamezole and Cirazoline. We observed This document is copyrighted by the American Psychological Association or one of its allied publishers.
alterations in USV intensity, bandwidth, and peak frequency with modulation of each receptor. Wright et al. (2012) reported no changes in call rate with Atipamezole without amphetamine and few changes in call profile (increase in step and short calls) with amphetamine. Our results are partially consistent with this, as we did not observe changes in call rate and the only change in call profile was a decrease in step calls with Atipamezole. Taken together, these results indicate that the ␣ 2 -AR may contribute to the types of calls produced, but that the contribution may be dependent upon context. Specifically, call profile changes when amphetamine is used to induce USV (Wright et al., 2012) and this differs from the call profile when a social, mating paradigm is used (current study). Given that amphetamine alone can induce changes in USV production, (Ahrens, Ma, Maier, Duvauchelle, & Schallert, 2009; Brudzynski et al., 2011; Burgdorf, Knutson, Panksepp, & Ikemoto, 2001; Wright et al., 2010 Wright et al., , 2012 Wright et al., , 2013 it is possible that amphetamine effects on both dopamine and NE could account for these differences. There are some minor methodologic differences in doses but route and timing were consistent. An alternative, but not mutually exclusive, explanation is that context matters. 
Limitations and Clinical Implications
The effects (or lack of effects) observed are limited to the dose ranges specifically tested in this study. In a diseased state, the effects of these drugs and doses might not be the same due to the up/down regulation of noradrenergic-ARs because of the disease process. However, this study suggests that noradrenergic mechanisms are involved in the modulation of pertinent vocal parameters and in some cases Propranolol result in potentially desirable effects (increased call rate and intensity).
Rat USVs are currently being used at the preclinical level to study the effects elicited by different classes of drugs, and to study the neurobiological mechanisms of these effects. Interestingly, we found that Propranolol increased intensity, or loudness, of USV. Reduced loudness is a hallmark feature of dysphonia in humans with Parkinson's disease (Darley, Aronson, & Brown, 1968 , 1975 Ho, Iansek, Marigliani, Bradshaw, & Gates, 1999; Plowman-Prine et al., 2009 ) and likewise, is almost universally affected in rodent models of Parkinson's disease (Ciucci et al., 2007 Gombash et al., 2013; Grant et al., 2014; Grant, Barnett, et al., 2015; Grant, Kelm-Nelson, et al., 2015) . We also found increased duration of complex calls with Cirazoline and Atipamezole. While the mechanisms underlying this increase are not clear, some potential explanations include increased arousal and/or attention (Berridge, Arnsten, & Foote, 1993; Berridge & Waterhouse, 2003) and increased sexual motivation. (Pertovaara, Haapalinna, Sirviö, & Virtanen, 2005; Viitamaa, Haapalinna, & Agmo, 2006) However, while Atipamezole has been shown to increase sexual activity and NE activity in regions important for mediating sexual behavior, (Pertovaara et al., 2005; Viitamaa et al., 2006) we did not observe differences in latency to mount for any of the drugs used in this study. Propranolol also increased call rate, which was not the case in previous work (Wright et al., 2012) . This discrepancy is likely due to methodological differences in how calls are elicited, as the dose range used in Wright et al. (2012) included all the doses used in the current study. The findings in the present study indicate that noradrenergic receptors (specifically the ␣ 2 -AR and ␤-AR) may be viable targets for attenuating voice deficits in Parkinson's disease-particularly vocal intensity.
Relevance to Disease States
Parkinson's disease is devastating to voice and communication function, negatively influencing social interactions and quality of life (Ho et al., 1999; Plowman-Prine et al., 2009 ). Voice and communication deficits do not respond to standard interventions targeting the primary disease pathology of nigrostriatal dopamine depletion (Dromey, Kumar, Lang, & Lozano, 2000; Klostermann et al., 2008; Narayana et al., 2009; Pintoet al., 2004; Schulz & Grant, 2000) . The refractory nature of dysphonia to levodopa along with evidence that voice deficits may emerge early in the progression of Parkinson's disease prior to significant nigrostriatal dopamine loss (Harel, Cannizzaro, Cohen, Reilly, & Snyder, 2004; Rusz et al., 2011 Rusz et al., , 2013 Stewart et al., 1995) , implicate other mechanisms. These data suggest that the neuropathology underlying dysphonia could involve NE mechanisms.
In humans, NE has been implicated in the treatment of cognitive and motor dysfunction in Parkinson's disease (Marien et al., 2004; Rommelfanger & Weinshenker, 2007) . Likewise, vocal communication deficits associated with potential NE involvement have been observed in transgenic and genetic models of Parkinson's disease (Grant et al., 2014 . For example, mice overexpressing human wild-type alpha-synuclein (aSyn; Thy1-aSyn) show alterations in call profile, intensity and duration of USV, (Grant et al., 2014) while Pink1 Ϫ/Ϫ rats demonstrate reduced intensity, bandwidth, and peak frequency of USV . In both the transgenic mouse and genetic rat models, vocalization deficits emerge early, independent of nigrostriatal dopamine loss, and each have neuropathological findings in the locus coeruleus, such as aSyn aggregates in the Thy1-aSyn mouse model (Fernagut et al., 2007) and aSyn aggregates and reduced tyrosine hydroxylase-immunoreactivity in Pink1 Ϫ/Ϫ rat model . Reductions in tyrosine hydroxylase-immunoreactivity in the locus coeruleus of Pink1 Ϫ/Ϫ rats is significantly correlated with reductions in intensity, indicating that reductions in norepinephrine may contribute to decreased loudness in this model . The Pink1 Ϫ/Ϫ rat also shows reductions in norepinephrine protein concentrations in the locus coeruleus in conjunction with increases in catechol-O-methyltransferase mRNA, the key enzyme in norepinephrine degradation (KelmNelson, Trevino, & Ciucci, 2018) . However, these studies merely indicate a relationship between norepinephrine and vocal control. The results from the current study provide further evidence those alterations to NE signaling may contribute to vocal deficits in disease states.
Conclusions
We observed that alterations in NE signaling (increases and decreases) impact multiple USV parameters while preserving gross locomotor behaviors, underscoring a possible dissociation of This document is copyrighted by the American Psychological Association or one of its allied publishers.
USV (axial deficits) from gross motor function in the limb (appendicular deficits). These findings validate and extend previous work demonstrating that general features such as call profile and rate change with administration of NE agonists and antagonists. In addition, drugs that act at different AR subtypes alter USV parameters in similar ways, suggesting that there might be an optimal range of noradrenergic signaling in which vocal motor control functions best. Finally, two drugs (Atipamezole and Propranolol) increased vocal loudness (intensity), indicating that NEmodulating drugs may be effective for attenuating Parkinson's disease-induced voice deficits, which are currently undertreated.
